This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Over the last 25 years, the headcount in the medicines manufacturing sector has fallen by 7,000 and since 2009 production volumes have fallen by nearly a third (29%), suggesting “faltering attractiveness” of the UK for manufacturing. ” Image from the Association of the British Pharmaceutical Industry (ABPI).
In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009. In the last 15 years, there has been a noticeable shift towards many prominent players effectively outsourcing innovation to start-ups due to the increasing cost of R&D.
Implementing PAT in (bio)pharmaceuticalmanufacturing New sensors or larger equipment with more complex setups (software and hardware) require stringent procedures to become fully implemented in a good manufacturing practice (GMP) manufacturing facility. International Council for Harmonisation (ICH), 2009.
billion in civil damages to states affected by the opioid crisis, which the Department of Justice said was the largest penalties ever levied against a pharmaceuticalmanufacturer. It admitted to bribing two doctors to write more prescriptions of OxyContin as well as other drugs between June 2009 and March 2017.
Consequently, the implementation of track and trace systems for pharmaceuticals is becoming more important as countries make it a legal requirement. For example, Turkey will require track and trace by 1 January 2009 and California is requiring the technology by 1 January 2011.
The WHO said there have been other fatalities in the same vein: in 1995 in Haiti and again in 2006 in Panama which led to the United States Pharmacopoeia (USP) adopting a Gas Chromatography (GC) method capable of separating and quantifying ethylene glycol and diethylene glycol in Glycerin in a revised monograph from 2009.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content